Tilray Brands (TLRY) Income from Non-Controlling Interests (2020 - 2026)

Tilray Brands (TLRY) posted Income from Non-Controlling Interests of $1.6 million for Q1 2026, down 20.11% on a QoQ basis from $1.9 million in Q4 2025, and up 137.99% year-over-year from $654217.8 in Q1 2025.

Tilray Brands (TLRY) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends

Tilray Brands' Income from Non-Controlling Interests history runs 7 years deep, the most recent figure standing at $1.6 million for Q1 2026.

  • Quarterly Income from Non-Controlling Interests rose 137.99% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $11.0 million (down 33.48% YoY) and the FY2025 annual result came in at $5.4 million, down 76.16% from the prior year.
  • Income from Non-Controlling Interests was $1.6 million for Q1 2026 at Tilray Brands, down from $1.9 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $39.6 million in Q2 2022 and bottomed at -$12.3 million in Q1 2024.
  • A 5-year average of $6.1 million and a median of $2.8 million in 2023 frame the typical range for Income from Non-Controlling Interests.
  • Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests jumped 688.99% — and 2024, when it slumped 704.85%.
  • Tilray Brands' Income from Non-Controlling Interests stood at $7.8 million in 2022, then plunged by 63.91% to $2.8 million in 2023, then tumbled by 128.99% to -$819000.0 in 2024, then jumped by 337.97% to $1.9 million in 2025, then slipped by 20.11% to $1.6 million in 2026.
  • Business Quant data shows TLRY's Income from Non-Controlling Interests at $1.6 million in Q1 2026, $1.9 million in Q4 2025, and $1.8 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn -
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn -
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn 395,346.10
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn -
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn -12.70 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn -
10 Tilray Brands 454.65 Mn 394.45 Mn 54.95 Mn 1.56 Mn

Historic Data

Download Data
DateValue
Feb 28, 2026 1.56 Mn
Nov 30, 2025 1.95 Mn
Aug 31, 2025 1.81 Mn
May 31, 2025 5.66 Mn
Feb 28, 2025 -4.10 Mn
Nov 30, 2024 -819,000.00
Aug 31, 2024 5.05 Mn
May 31, 2024 16.37 Mn
Feb 29, 2024 -12.28 Mn
Nov 30, 2023 2.83 Mn
Aug 31, 2023 15.66 Mn
May 31, 2023 18.89 Mn
Feb 28, 2023 -1.53 Mn
Nov 30, 2022 7.83 Mn
Aug 31, 2022 7.69 Mn
May 31, 2022 39.57 Mn
Feb 28, 2022 -2.93 Mn
Nov 30, 2021 6.00 Mn
Aug 31, 2021 7.05 Mn
May 31, 2021 -6.72 Mn